Allison Park, PA, United States of America

Justus B Cohen

USPTO Granted Patents = 13 (Patent Applications = 6)

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 3.9

ph-index = 4

Forward Citations = 46(Granted Patents)

Location History:

Pittsburgh, PA (US) (2017 - 2020)
Allison Park, PA (US) (2017 - 2024)

Company Filing History:

13 out of 1,860

University of Pittsburgh

patents

1 out of 2,595

University of Pennsylvania

patents

where one patent can have more than one assignee

Years Active: 2017-2025

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12414973 - Antigenically stealthed oncolytic viruses (2025-09-16),

2. 11883448 - Oncolytic HSV vector (2024-01-30),

3. 11419926 - Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-HSV receptors (2022-08-23),

4. 10851354 - TRPV1 modulatory gene product that affects TRPV1-specific pain behavioral responses identified in a functional screen of an HSV-based cDNA library (2020-12-01),

5. 10576115 - Oncolytic HSV vector (2020-03-03),

6. 10328136 - Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-HSV receptors (2019-06-25),

7. 10201575 - Oncolytic HSV vector (2019-02-12),

8. 10188686 - Oncolytic HSV vector (2019-01-29),

9. 10174341 - Non-toxic HSV vectors for efficient gene delivery applications and complementing cells for their production (2019-01-08),

10. 10172893 - Oncolytic HSV vector (2019-01-08),

11. 10160959 - TRPV1 modulatory gene product that affects TRPV1-specific pain behavioral responses identified in a functional screen of an HSV-based cDNA library (2018-12-25),

12. 9593347 - Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-HSV receptors (2017-03-14),

13. 9580699 - TRPV1 modulatory gene product that affects TRPV1-specific pain behavioral responses identified in a functional screen of an HSV-based cDNA library (2017-02-28),

Title: Justus B Cohen: Pioneering Innovator in Oncolytic HSV Vectors

Introduction:

Justus B Cohen, a trailblazing inventor based in Allison Park, PA, is a visionary in the realm of technology and medical advancements. With a plethora of patents under his name, his unwavering dedication to innovation continues to shape the landscape of modern medicine.

Latest Patents:

Amongst his many contributions, Justus B Cohen's latest patents stand out as groundbreaking developments in the field of oncolytic therapy. One such invention is the Oncolytic HSV vector, a recombinant Herpes Simplex Virus designed to target and destroy cancer cells with precision. Additionally, his identification of mutations in herpes simplex virus envelope glycoproteins has paved the way for enhanced vector retargeting to novel non-HSV receptors, revolutionizing targeted therapy approaches.

Career Highlights:

Notably, Justus B Cohen is affiliated with the renowned University of Pittsburgh—of the Commonwealth System of Higher Education. His tenure at this esteemed institution has been marked by a fervent pursuit of innovative solutions to complex medical challenges. With a total of 12 patents to his name, he has consistently demonstrated a knack for pushing the boundaries of scientific discovery.

Collaborations:

In his quest for excellence, Justus B Cohen has had the privilege of working alongside esteemed colleagues such as Joseph C Glorioso, III and Hiroaki Uchida. These collaborative efforts have not only fostered a culture of teamwork but have also resulted in synergistic breakthroughs that continue to redefine the possibilities within the realm of medical research.

Conclusion:

Justus B Cohen's profound impact on the world of oncolytic therapy is undeniable. His pioneering spirit, coupled with his relentless pursuit of excellence, serves as a beacon of inspiration for aspiring inventors and researchers alike. As we look towards the future, it is clear that Justus B Cohen's legacy will endure, shaping the course of medical innovation for generations to come.

This text is generated by artificial intelligence and may not be accurate.